Recent Quotes

My Watchlist

Indicators

MediWound Ltd. - Ordinary Shares (NQ: MDWD )

16.49 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	16.49
Bid (Size)	16.40 (7)
Ask (Size)	17.00 (1)
Prev. Close	16.49
Today's Range	16.49 - 16.49
52wk Range	10.14 - 24.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

December 17, 2024

From MediWound Ltd.

Via GlobeNewswire

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

November 27, 2024

Via Benzinga

Performance

YTD	+46.58%	+46.58%
1 Month	+0.06%	+0.06%
3 Month	-5.88%	-5.88%
6 Month	+13.57%	+13.57%
1 Year	+59.94%	+59.94%

More News

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

November 26, 2024

From MediWound Ltd.

Via GlobeNewswire

Earnings Scheduled For November 26, 2024

November 26, 2024

Via Benzinga

Earnings Preview: MediWound

November 25, 2024

Via Benzinga

MediWound to Report Third Quarter 2024 Financial Results

November 12, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

October 10, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

October 08, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

August 15, 2024

From MediWound Ltd.

Via GlobeNewswire

MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024

August 14, 2024

Via InvestorPlace

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

August 14, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

August 05, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound to Report Second Quarter 2024 Financial Results

August 02, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

July 29, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

July 16, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Announces $25 Million Strategic Private Placement Financing

July 15, 2024

From MediWound Ltd.

Via GlobeNewswire

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

July 05, 2024

Via Benzinga

US Stocks Mixed; Jobs Figures Top Estimates For June

July 05, 2024

Via Benzinga

Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

July 05, 2024

Via Benzinga

MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024

May 29, 2024

Via InvestorPlace

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

April 25, 2024

From MediWound Ltd.

Via GlobeNewswire

MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session

April 17, 2024

Via Investor Brand Network

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.